Literature DB >> 29023856

To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.

Cristina Scarpazza1, Luca Prosperini2, Nicola De Rossi1, Lucia Moiola3, Maria Pia Sormani4, Simonetta Gerevini5, Ruggero Capra1.   

Abstract

OBJECTIVE: To retrospectively analyze the effect of plasma exchange (PLEX; yes = PLEX+ , no = PLEX- ) and steroids administration timing (prophylactically [proST] or therapeutically [therST]) on the longitudinal clinical course of patients with natalizumab-related progressive multifocal leukoencephalopathy (PML) and full-blown immune reconstitution inflammatory syndrome (PML-IRIS).
METHODS: Clinical and radiological data of 42 Italian patients with PML were analyzed. Patient's data are available until 12 months after PML diagnosis. PLEX and steroids treatment as time-dependent covariates were entered in: (1) a Cox model to investigate their impact on full-blown PML-IRIS latency; (2) an analysis of variance ANOVA to investigate their impact on IRIS duration; and (3) a linear mixed model to assess their impact on the longitudinal clinical course (measured by means of Expanded Disability Status Scale [EDSS]).
RESULTS: Treatment with PLEX was not associated to PML-IRIS latency (hazard ratio [HR] = 1.05; p = 0.92), but once IRIS emerged, its duration was significantly longer in patients who underwent PLEX (101 vs 54 days in PLEX+ and PLEX- patients; p = 0.028). Receiving proST versus therST was not associated to IRIS latency (HR = 0.67; p = 0.39) or duration (p = 0.95). Patients who underwent proST had a significantly higher EDSS increase during PML (0.09 EDSS points per month; p = 0.04) as compared to those who had therST.
INTERPRETATION: This study highlights that: (1) caution on the use of PLEX should be considered as the current data do not support a beneficial effect of PLEX and (2) caution on the early use of steroids is suggested because their prophylactic use to prevent full-blown PML-IRIS seems to negatively impact on the longitudinal disability course. Ann Neurol 2017;82:697-705.
© 2017 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29023856     DOI: 10.1002/ana.25070

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  11 in total

1.  Four cases of natalizumab-related PML: a less severe course in extended interval dosing?

Authors:  Cristina Scarpazza; Nicola De Rossi; Giulietta Tabiadon; Maria Vittoria Turrini; Simonetta Gerevini; Ruggero Capra
Journal:  Neurol Sci       Date:  2019-06-07       Impact factor: 3.307

Review 2.  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors:  Babak Soleimani; Katy Murray; David Hunt
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

Review 3.  Advances in Treatment of Progressive Multifocal Leukoencephalopathy.

Authors:  Raphaël Bernard-Valnet; Igor J Koralnik; Renaud Du Pasquier
Journal:  Ann Neurol       Date:  2021-09-07       Impact factor: 11.274

Review 4.  Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration.

Authors:  S Richard Dunham; Robert Schmidt; David B Clifford
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

5.  Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.

Authors:  Luca Prosperini; Revere P Kinkel; Augusto A Miravalle; Pietro Iaffaldano; Simone Fantaccini
Journal:  Ther Adv Neurol Disord       Date:  2019-03-29       Impact factor: 6.570

6.  Severe Progressive Multifocal Leukoencephalopathy (PML) and Spontaneous Immune Reconstitution Inflammatory Syndrome (IRIS) in an Immunocompetent Patient.

Authors:  Lea Krey; Peter Raab; Romilda Sherzay; Georg Berding; Matthias Stoll; Martin Stangel; Florian Wegner
Journal:  Front Immunol       Date:  2019-05-28       Impact factor: 7.561

7.  Treatment of natalizumab-associated PML with filgrastim.

Authors:  Dusan Stefoski; Roumen Balabanov; Rasha Waheed; Michael Ko; Igor J Koralnik; Fabian Sierra Morales
Journal:  Ann Clin Transl Neurol       Date:  2019-04-08       Impact factor: 4.511

Review 8.  To Go or Stay: The Development, Benefit, and Detriment of Tissue-Resident Memory CD8 T Cells during Central Nervous System Viral Infections.

Authors:  Taryn E Mockus; Heather M Ren; Aron E Lukacher
Journal:  Viruses       Date:  2019-09-11       Impact factor: 5.048

Review 9.  Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring.

Authors:  Kathy Khoy; Delphine Mariotte; Gilles Defer; Gautier Petit; Olivier Toutirais; Brigitte Le Mauff
Journal:  Front Immunol       Date:  2020-09-24       Impact factor: 7.561

Review 10.  Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.

Authors:  Irene Cortese; Daniel S Reich; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2020-11-20       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.